



**Supplemental Fig. 1. AdipoQ had no effect on the migration and invasion of BxPC-3 and CFPAC-1 cells.** A, The BxPC-3 cells were left untreated or were treated with AdipoQ (40  $\mu\text{g/ml}$ ), and then subjected to transwell migration assays. B, The relative migration rate was exhibited as the ratio of the percent migration of AdipoQ-treated cells normalized to the control cells. C, the matrigel invasion assays were carried out in BxPC-3 cells treated with or without AdipoQ. D, The invasion rate of AdipoQ treated cells was normalized to the control cells. Data are expressed as the mean  $\pm$  SEM of 3 independent experiments.



**Supplemental Fig. 2. Adiponectin had no significant effect on cyclinA2, cyclinE1 and p21 expression in BxPC-3 cells.** BxPC-3 cells were left untreated or were treated with adiponectin (40  $\mu$  g/ml) for 48h, and then subjected to western blot analysis of the protein expression of cyclin A2 (A), cyclin E1(C) and p21(E). The qualification result of cyclin A2, cyclin E1 and p21 protein levels are shown in (B), (D) and (F) separately. AdipoQ, adiponectin.



**Supplementary Fig. S3. Adiponectin inhibited the proliferation of PANC-1 cells and cyclin D1 expression in PANC-1 cells.** A, PANC-1 cells were left untreated or treated with AdipoQ (40  $\mu$ g/ml) for 48h or 72h, and then the cell proliferation was determined via CCK8 assay. The results are expressed as the absorbance at 450 nm. B, cyclin D1 mRNA levels in adipoQ-treated PANC-1 cells were analyzed by real-time PCR. Similar results were seen in 3 independent experiments. AdipoQ, adiponectin. Data are expressed as the mean  $\pm$  SEM. \* $P$  < 0.05; \*\* $P$  < 0.01.

**Table S1.** Primers used in this study

Primer name	Sequences
<b>For cloning</b>	
AdipoQ-FL-F	5'-ATCTAGAGCCACCATGAGGGCCTGGATCTTCTT
AdipoQ-FL-R	5'-GGCGTCGACTTATTTTTCGAACTGTGGGT
<b>For quantitative PCR</b>	
E2F1-F	5'-ACGTGACGTGTCAGGACCT
E2F1-R	5'-GATCGGGCCTTGTTTGCTCTT
E2F2-F	5'-CGTCCCTGAGTTCCCAACC
E2F2-R	5'-GCGAAGTGTCATACCGAGTCTT
E2F3-F	5'-GTATGATACGTCTCTTGGTCTGC
E2F3-R	5'-CAAATCCAATACCCCATCGGG
CDK2-F	5'-CCAGGAGTTACTTCTATGCCTGA
CDK2-R	5'-TTCATCCAGGGGAGGTACAAC
CDK4-F	5'-ATGGCTACCTCTCGATATGAGC
CDK4-R	5'-CATTGGGGACTCTCACACTCT
CDK6-F	5'-CCAGATGGCTCTAACCTCAGT
CDK6-R	5'-AACTTCCACGAAAAAGAGGCTT
TAF5-F	5'-CCGGGTAAAGTTGGAAGTGTT
TAF5-R	5'-CCTTGTTGGTTGTAGGCTGAC
ANKRD1-F	5'-AGTAGAGGAACTGGTCACTGG
ANKRD1-R	5'-TGTTTCTCGCTTTTCCACTGTT
RUNX2-F	5'-TGGTACTGTCATGGCGGGTA
RUNX2-R	5'-TCTCAGATCGTTGAACCTTGCTA
AdipoR1-F	5'-GTCATAGACCTCCCATGCCC
AdipoR1-R	5'-GCACGAAACCAAGCAGATGG
AdipoR2-F	5'-CTGGATGGTACACGAAGAGGT
AdipoR2-R	5'-TGGGCTTGTAAGAGAGGGGAC
GAPDH-F	5'-AAGAAGGTGGTGAAGCAGG
GAPDH-R	5'-GTGGTCGTTGAGGGCAAT
TCF7L2-F	5'-CAAATCCCCCATCCGCTAGG
TCF7L2-R	5'-GGGACCATAATGGGGAGGGAA
AdipoQ-F	5'-ATGGCCCCTGCACTACTCTA
AdipoQ-R	5'-CAGGGATGAGTTCGGCACTT
$\beta$ -catenin-F	5'-TCCGAATGTCTGAGGACAAG
$\beta$ -catenin-R	5'-TCAGCAGTCTCATTCCAAGC
cyclinD1-F	5'-CTCCTGGTGAACAAGCTCAA
cyclinD1-R	5'-TGAACTTCACATCTGTGGCA
CEBPA-F	5'-TATAGGCTGGGCTTCCCCTT
CEBPA-R	5'-AGCTTTCTGGTGTGACTCGG

AdipoQ, adiponectin